Physician profile
Laurel Win Yap
NPI 1801058490
$13,100.75
in general payments reported to CMS, 2019-2025
30 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $470 · 2021: $1,133 · 2022: $1,812 · 2023: $2,135 · 2024: $3,008 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,764 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,764.07 |
| Education | $550.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,465.47 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $1,115.47 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $1,090.34 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $999.88 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $955.27 | 2019-2025 | Rayaldee |
| Amgen INC. | $823.25 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Glaxosmithkline, LLC. | $770.16 | 2021-2025 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $767.22 | 2019-2025 | Vafseo, Auryxia |
| Ani Pharmaceuticals, INC. | $629.60 | 2023-2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $574.12 | 2020-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.30 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $375.27 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $293.98 | 2020-2025 | Acthar |
| Amarin Pharma, INC. | $285.08 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $241.35 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $233.10 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $201.21 | 2022-2025 | Lupkynis |
| Sumitomo Pharma America, INC. | $116.64 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $112.48 | 2021-2023 | Rybelsus, Ozempic |
| Fresenius USA Manufacturing, INC. | $91.78 | 2025 | |
| Ardelyx, INC. | $90.14 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.28 | 2025 | Voyxact |
| Lilly USA, LLC | $55.88 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $55.69 | 2023 | Krystexxa |
| Abbvie INC. | $39.97 | 2019-2021 | |
| Genzyme Corporation | $24.39 | 2025 | |
| Ibsa Pharma INC. | $21.28 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.53 | 2019 | |
| Merck Sharp & Dohme LLC | $17.90 | 2022 | |
| Shire North American Group INC | $16.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.